# HepaRegeniX

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/heparegenix

- Industry: Biotechnology
- Headquarters: Tubingen, Germany
- Website: www.heparegenix.com
- Total disclosed funding: $62M
- Latest round: Series C (Mar 17, 2025)
- Investors on record: 7

## About

Based in Germany, HepaRegeniX GmbH develops innovative therapies focused on liver regeneration, aiming to improve the treatment of acute and chronic liver diseases through advanced regenerative techniques.HepaRegeniX GmbH, founded in 2017, specializes in creating therapies for liver diseases. The company is headquartered in Tübingen, Germany. The founder, Stefan Laufer, has a history in biotechnology and has previously established other ventures. HepaRegeniX has completed a total of 5 funding deals, with the most recent being a Series C round on March 17, 2025, raising EUR 21.5 million led by Wellington Partners, alongside investors Novo Holdings and Vesalius Biocapital. This funding brings the total amount raised to EUR 21.5 million and positions the company with a valuation of EUR 571.729 million.HepaRegeniX GmbH specializes in developing innovative therapies aimed at treating acute and chronic liver diseases through the mechanism of liver regeneration. The company’s primary product, HRX-215, is a novel regenerative therapy designed to reverse disease progression associated with liver conditions, specifically addressing patients suffering from liver ailments. The primary customer base includes healthcare providers and institutions such as hospitals and clinics that administer these therapies to patients. HepaRegeniX’s products are primarily marketed in European regions and are expanding into the United States as they prepare for upcoming clinical trials.HepaRegeniX's revenue generation strategy focuses on clinical partnerships and collaborations within the healthcare sector. The company works with healthcare providers and research institutions to facilitate the use of its flagship product, HRX-215, through structured partnerships that may involve licensing or direct sales to hospitals and clinics seeking advanced treatment options for liver diseases. As the company progresses through clinical trials and regulatory approvals, revenue will likely be derived from successful product launches and ongoing collaborations with medical institutions, fostering long-term relationships that ensure access to its regenerative therapies for liver disease management.HepaRegeniX intends to utilize the EUR 21.5 million raised in Series C funding to finalize its Phase Ib study and launch the Phase IIa clinical trial for HRX-215, its leading therapy aimed at promoting liver regeneration. The company has plans to expand into the United States market, targeting a timeline aligned with the completion of clinical trials. The strategic application of recent funding will support these initiatives, paving the way for potential product launches and increased market penetration.

## Funding rounds

- Series C, Mar 17, 2025, $23M — Wellington Partners, Novo Holdings, Vesalius Biocapital
- Series C, Jun 19, 2024, $16M — Novo Holdings, Vesalius Biocapital, Boehringer Ingelheim Venture, High-Tech Gruenderfonds
- Series B, Oct 5, 2021 — Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Novo Holdings, Ascenion GmbH, Coparion
- Series B, Dec 19, 2019, $12M — Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Novo Holdings, Ascenion GmbH, Coparion
- Series A, Nov 4, 2016, $10M — Novo Holdings, Boehringer Ingelheim Venture, High-Tech Gruenderfonds, Coparion

## Investors

- Novo Holdings — Series A, Series B, Series C
- Boehringer Ingelheim Venture (https://capitalatlas.ai/funds/boehringer-ingelheim-venture) — Series A, Series B, Series C
- High-Tech Gruenderfonds (https://capitalatlas.ai/funds/high-tech-gruenderfonds) — Series A, Series B, Series C
- Coparion (https://capitalatlas.ai/funds/coparion) — Series A, Series B
- Ascenion GmbH — Series B
- Vesalius Biocapital (https://capitalatlas.ai/funds/vesalius-biocapital) — Series C
- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series C